Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
EMBER trial (imlunestrant): what clinicians have said so far
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
- NCT04188548 ↗
- Active, not recruiting
- Eli Lilly and Company
- Deep size, estimated: 301+ verified statements
We haven't built an HCP commentary report on EMBER (imlunestrant; imlunestrant plus abemaciclib; imlunestrant plus everolimus in ER+ advanced breast cancer and endometrial cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EMBER so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 15 YouTube videos | |
| 7 podcast episodes | |
| 4 posts on X |
The trial
ClinicalTrials.gov- Official title
- EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; Endometrial Cancer
- Interventions
- LY3484356; Abemaciclib; Everolimus; Alpelisib; Trastuzumab; Aromatase Inhibitor (AI); Pertuzumab
- Arms
- Dose Escalation LY3484356 · Experimental
- Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI · Experimental
- Part B: Dose Expansion: Cohort E3: LY3484356 · Experimental
- Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus · Experimental
- Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib · Experimental
- Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib · Experimental
- Part D: Dose Expansion: LY3484356 +/- Abemaciclib · Experimental
- Part E: Dose Expansion: LY3484356 + Trastuzumab + Pertuzumab · Experimental
- Enrollment
- 379
- Primary outcomes
- Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities
- Sponsor
- Eli Lilly and Company
- Start
- Dec 10, 2019
- Primary completion
- Jun 29, 2020
- Results posted
- No
- Registry record
- NCT04188548 · updated Jun 22, 2026
Publications
linked from the registry- Bhave M, Jhaveri KL, Kaufman PA, Aftimos P, Lombard J, Giridhar KV, Im SA, Ma CX, Lee KT, Kim SB, Sohn J, Li Y, Yuen E, Estrem ST, Nguyen B, Makena MR, Ismail-Khan R, Beeram M. Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study. Breast Cancer Res. 2025 Dec 21;28(1):18. doi: 10.1186/s13058-025-02168-6. PubMed 41423595
- Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C, Bhave M, Kaufman PA, Beck JT, Manso Sanchez L, Parajuli R, Wang HC, Tao JJ, Im SA, Harnden K, Yonemori K, Dhakal A, Neven P, Aftimos P, Pierga JY, Lu YS, Larson T, Jerez Y, Sideras K, Sohn J, Kim SB, Saura C, Bardia A, Sammons SL, Bacchion F, Li Y, Yuen E, Estrem ST, Rodrik-Outmezguine V, Nguyen B, Ismail-Khan R, Smyth L, Beeram M. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study. J Clin Oncol. 2024 Dec 10;42(35):4173-4186. doi: 10.1200/JCO.23.02733. Epub 2024 Sep 6. PubMed 39241211